About InNexus Biotechnology

InNexus Biotechnology, Inc., a drug development company, focuses on commercializing the monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology. The company’s DXL technology seeks to improve the therapeutic potency of existing monoclonal antibody products by increasing the binding to target antigen, enhancing antibody effector functions, and installing new properties into antibodies. The company has commenced multiple projects related to the commercialization of DXL technology for improving the therapeutic potency of existing monoclonal antibody products, DXL625, DXL702, DXL1218, and development efforts related to specific products. DXL diagnostics is an improved antibody-based diagnostics test and the company’s DXL mouse would facilitate in vivo recombinant production techniques of DXL antibodies. Collaborations Protokinetix, Inc: The company announced that it had granted a license to Protokinetix, Inc. of Vancouver, B.C. for the use of its DXL technology with up to three antibodies. GlaxoSmithKline: The company entered into a research and development agreement and a license agreement with Corixa Corp. of Seattle, WA, which allows both parties to perform a collaborative study to evaluate the feasibility and potential for DXL technology to be used with certain of the proprietary monoclonal antibodies and monoclonal antibodies under development by Corixa. Mayo Clinic Arizona: The company entered into a collaborative research agreement with Mayo Clinic targeted at advancing the development of monoclonal antibody. Epitomics Inc: The company entered into a co-development arrangement for its TransMab Antibody Technology with Epitomics Inc. of Burlingame, California. Under the terms of the agreement, Epitomics would supply humanized antibodies for certain intracellular targets that have been identified by the parties. Affimed Therapeutics AG: The company entered into a collaboration agreement with Affimed Therapeutics AG. Under the terms of the agreement, the companies would complete feasibility studies and the company would have a right to license one of Affimed’s antibodies while Affimed would have the right to license DXL technology for one antibody. Arana Inc: The company entered into a collaboration agreement with EvoGenix to evaluate the use of its DXL technology in combination with an antibody for the treatment of certain viral infections. BioInvent International AB: The company entered into an agreement with BioInvent for the provision of the company’s DXL technology with a BioInvent therapeutic antibody, targeting cancer. Under the agreement the parties would perform collaborative R&D aimed at a single target. Peptech Limited (now Arana Inc.): The company entered into a collaboration agreement with EvoGenix , which was subsequently acquired by Peptech Limited. The agreement is to evaluate the use of the company’s’ DXL technology in combination with an antibody for the treatment of certain viral infections. If the technology is proven to enhance antiviral activity, the company would participate in the development of a new generation of high value therapeutic products. This collaboration contemplates an exploratory use of DXL technology. Royalty Pharma: The company’s subsidiary, InNexus Biosciences (Barbados) Inc., entered into an agreement with RP Dynamic Cross Linking LP to sell rights to potential advance revenues for DXL products to be developed with specific limited technology rights owned by the company and a specific antibody selected by Royalty Pharma. Competition The company’s competitors include Vanderbilt University, Medarex Inc., Seattle Genetics, and ImmunoGen, Inc. Significant Events On December 10, 2009, InNexus Biotechnology Inc. and XERIS Pharmaceuticals, Inc. announced a research collaboration in which the companies would pursue development of a potential subcutaneous delivery of InNexus' Dynamic Cross Linking antibodies using XERIS' proprietary formulation-injection technologies. On May 27, 2010, the company has entered into a collaboration agreement with the National Cancer Institute of the U.S. National Institutes of Health to research proprietary technologies developed by the company. Antibodies are the chosen drug development platform for pharmaceutical companies and DXL has been shown to improve antibody performance.